Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Acerta Pharma BV
Case Comprehensive Cancer Center
University of California, San Diego
Cedars-Sinai Medical Center
OrphAI Therapeutics
Fate Therapeutics
Mayo Clinic
M.D. Anderson Cancer Center
AbbVie
MEI Pharma, Inc.
M.D. Anderson Cancer Center
Brown University
Aptevo Therapeutics
Gilead Sciences
Genentech, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Swiss Cancer Institute
Hoffmann-La Roche
Wake Forest University Health Sciences
Dartmouth-Hitchcock Medical Center
Duke University
Georgetown University
National Institutes of Health Clinical Center (CC)
Aptevo Therapeutics
Genentech, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Celgene Corporation
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Georgetown University
Merck Sharp & Dohme LLC
CTI BioPharma
Emory University
University of Alabama at Birmingham
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
AbbVie
National Cancer Institute (NCI)